Q1 2023 Non-GAAP Operating Income

Quarterly GAAP Income Statement $ millions, except EPS Revenues Q1 2023 Q1 2023 Margins Q1 2022 Q1 2022 Margins Change 3,661 3,661 0% COGS Gross profit R&D 2,079 56.8% 1,921 52.5% 8% 1,582 1,740 (9%) 43.2% 47.5% (4.3%) 234 6.4% 225 6.2% 4% S&M 546 14.9% 584 15.9% (6%) G&A 296 8.1% 296 8.1% (0%) Legal settlements and loss contingencies 233 6.4% 1,124 30.7% (79%) Impairments, restructuring and others 274 7.5% 276 7.5% (1%) Other income (2) (0.1%) (52) (1.4%) (96%) 2 (713) (100%) Operating income (loss) 0.1% (19.5%) 19.6% Financial expenses, net 260 7.1% 258 7.0% 1% Tax (19) 7.5%* 2 (0.2%)* N/A Minority and share in profit (34) (0.9%) (18) (0.5%) 89% Net income (loss) attributable to Teva (205) (5.6%) (955) (26.1%) (79%) # of shares (diluted, millions) 1,115 1,107 Earnings per share ($) (0.18) (0.86) | 31 | * Represents tax rate teva

View entire presentation